DuPont de Nemours, Inc (DD)
Key Takeaways:
Company Overview
DuPont is a global specialty materials and industrial solutions company focused on advanced applications in healthcare & water technologies and diversified industrials. Its portfolio includes medical packaging and device components, water filtration and purification systems, building materials, structural adhesives, lubricants, and engineered polymers/components used in aerospace, automotive, construction, and industrial markets. The company has spent several years reshaping itself through major divestitures and separations, most notably spinning off electronics into Qnity in 2025 and agreeing to sell Aramids, leaving a more focused but still complex portfolio. DuPont operates in about 50 countries and relies on differentiated materials science, application development, global manufacturing, and recognized brands such as TYVEK®, FILMTEC™, STYROFOAM™, CORIAN®, Vespel®, and MOLYKOTE®. The investment case now depends less on conglomerate breadth and more on whether the remaining businesses can sustain margin discipline, convert technical differentiation into pricing power, and manage meaningful legal, environmental, and separation-related liabilities.
Business Segments
Economic Moat Analysis
DuPont’s moat is best described as <strong>narrow</strong>, not wide. The company has real advantages in application engineering, regulatory know-how, patents, and entrenched positions in mission-critical end markets such as healthcare and water treatment. Those attributes can make it harder for customers to switch quickly. However, the business mix is still exposed to cyclical industrial demand, competitive pricing pressure, and regulatory/legal overhangs. The portfolio has also been in persistent transition, which weakens the case for a durable, consolidated moat because it introduces execution risk and obscures the stability of earnings power. In short, DuPont has pockets of strong defensibility, but not a broad, structural advantage across the whole company.
Several brands are widely recognized in specification-driven markets, which helps with customer trust and qualification, but brand alone does not create durable monopoly-like power.
In healthcare, water, and certain industrial applications, qualification, regulatory validation, and process integration create meaningful switching friction, though it is uneven across the portfolio.
A large patent and trade-secret estate supports differentiation, but patents expire, can be worked around, and do not fully protect against competing technologies or pricing pressure.
DuPont’s engineering, testing, and application-development expertise is a genuine advantage in regulated and mission-critical uses, where performance and reliability matter more than price alone.
Global manufacturing and sales presence improve customer access and service, but scale is not distinctive enough in itself to create a strong moat in a fragmented competitive landscape.
Some products are embedded in customer specifications and qualified processes, which can sustain demand, but this advantage can still erode if competitors offer superior economics or technology.
Key Strengths
- Portfolio focus: The company has substantially simplified its business mix, which should improve capital allocation, reduce internal complexity, and make operating performance easier to assess.
- Healthcare exposure: Medical packaging, device components, and biopharma-related products provide access to regulated end markets with generally better structural demand than cyclical industrials.
- Water demand: Filtration and purification technologies benefit from long-duration secular themes such as water scarcity, wastewater treatment, desalination, and higher purity standards.
- Brand equity: Well-known brands such as TYVEK®, FILMTEC™, STYROFOAM™, CORIAN®, Vespel®, and MOLYKOTE® support customer recognition and specification-based demand.
- Technical capability: DuPont’s application development, prototyping, and specialized manufacturing capabilities matter in regulated and mission-critical use cases, making substitution harder than in commodity chemicals.
- Improving margins: Operating EBITDA expanded in Healthcare & Water Technologies and remained resilient overall despite divestiture noise, indicating some ability to protect profitability.
- Liquidity buffer: Post-separation debt reduction and available credit facilities provide near-term financial flexibility, despite lower cash balances than a year earlier.
- Patent estate: A broad patent portfolio and trade-secret base can support product differentiation and some pricing resilience over time.
Identified Weaknesses
- Complex legacy: DuPont still carries material separation, indemnification, tax, and litigation overhangs from prior corporate transformations, which reduces analytical clarity.
- Low cash cushion: Cash and cash equivalents fell sharply after separation-related actions, leaving less balance-sheet slack than headline debt reduction may imply.
- Modest R&D intensity: R&D at roughly 3% of sales is not especially high for a technology-oriented company, which may limit long-term innovation depth.
- Cyclical exposure: Diversified Industrials remains tied to construction, automotive, aerospace, and packaging cycles, making results vulnerable to macro slowdowns.
- Margin volatility: Operating EBITDA in Diversified Industrials declined in 2025, showing that the remaining portfolio is not uniformly resilient.
- Asset impairment risk: Recent goodwill and asset write-downs indicate that some businesses or investments may not justify prior carrying values.
- Tax complexity: The effective tax rate has been highly volatile, reflecting restructuring, geographic mix, and transaction effects rather than stable underlying earnings quality.
- Dependency on execution: Expected value creation depends heavily on restructuring, integration of acquisitions, and successful post-separation cost discipline.
Growth Opportunities
- Water scarcity: Long-term demand for reverse osmosis, ion exchange, and wastewater treatment should support organic growth in Water Technologies.
- Medical outsourcing: Greater outsourcing and specialization in medical device and biopharma supply chains could support Spectrum, Donatelle, and related healthcare platforms.
- Construction stabilization: A flat-to-recovering North American construction environment could improve Building Technologies volumes after recent weakness.
- Aerospace recovery: Aerospace and related industrial markets may provide low-to-mid single-digit growth if production rates and supply chains normalize.
- Product mix: As the portfolio shifts further toward higher-value applications, pricing and mix could improve margins over time.
- Cost actions: Ongoing restructuring may improve fixed-cost absorption and remove stranded overhead if execution remains disciplined.
- Capital returns: The new buyback authorization could support per-share metrics if management avoids overpaying and cash generation holds up.
- Selective M&A: Small, targeted acquisitions in healthcare and water could deepen specification positions without requiring large balance-sheet commitments.
Risk Factors
- PFAS exposure: Legacy PFAS-related liabilities remain a major long-dated legal and cash-flow risk, with uncertainty around future claims, settlements, and indemnity recoveries.
- Regulatory pressure: Environmental, product stewardship, export-control, and antitrust scrutiny can raise costs, restrict sales, or force product/process changes.
- China risk: China-related demand, regulatory actions, and trade tensions create meaningful uncertainty, especially given the company’s international footprint.
- Tariff risk: Rising protectionism and supply-chain nationalism can increase input costs, disrupt logistics, and weaken customer demand.
- Customer destocking: Regulated and industrial customers can abruptly change inventory behavior, creating volume swings that are hard to forecast.
- Integration execution: Acquisitions and separations create operational distractions, IT risk, and the possibility of failing to realize expected synergies.
- Interest-rate risk: Although debt has been reduced, remaining obligations and refinancing needs still leave the company exposed to capital-market conditions.
- Competitive erosion: Well-capitalized multinationals and strong regional specialists can pressure pricing, especially where products are less differentiated.
Valuation Metrics
P/E is extremely high at 308.53 (forward P/E 16.31). This divergence suggests either (a) unusually weak/one-time depressed trailing earnings (ttm) or (b) accounting/charge effects. For valuation work, the forward multiple is more informative than the trailing P/E, but it still must be validated by consistency in earnings power.
PEG = 0.82, implying the current valuation is not excessive relative to expected growth (as modeled). PEG below 1 is generally more supportive for growth-at-a-reasonable-price setups—if the growth outlook is credible.
Price/Sales (P/S) is 2.12 and EV/Sales is 16.72. The elevated EV/Sales versus P/S often points to meaningful net debt and/or high balance-sheet drag relative to revenue; EV-based metrics matter here.
P/B is 1.27, which is near/below many industrials’ long-run averages—generally favorable for a value framing (not deeply “asset-expensive”).
P/C = 9.84 is high, suggesting cash generation (or classification) is relatively expensive vs. market price; combined with very high trailing P/E, it raises the question of cash vs. earnings durability.
Profit-to-capital multiples look mixed: ROE/ROIC are moderate (see profitability section), yet some valuation measures (P/FCF 9.54, EV/EBITDA 16.72) imply the market is still pricing a normalized earnings/EBITDA profile rather than the distressed ttm earnings.
Earnings & Profitability
EPS (ttm) is 0.23 while forward EPS next year is 7.96. That’s a very large step-up and strongly implies the ttm earnings are depressed (restructuring, charges, or cycle). This can be bullish for both value and growth if the normalization holds.
EPS this year is 1.87, EPS next quarter 43.88% (quarter growth rate shown) and EPS next year is 7.96. The trajectory suggests analysts expect a sharp rebound, but investors should demand evidence (guided results, margins, cash flow) rather than rely solely on projections.
Margin profile: Gross margin 32.74%, operating margin 15.32%, and net/profit margin 1.03%* (profit margin field shown as 1.03%). Wide gap between operating and net margin implies below-operating line items (interest, taxes, restructuring, other income/expense) are materially impacting bottom-line profitability.
Return metrics are low-to-moderate: ROA 0.37%, ROE -0.05%* (negative/near-zero), and ROIC 0.42% (all based on provided fields). That is not consistent with a high-quality, compounding earnings machine right now—yet forward EPS suggests a near-term normalization phase.
Growth Analysis
Analyst growth expectations look constructive: EPS next Y 7.96 vs EPS (ttm) 0.23 implies very strong modeled rebound. Sales Y/Y TTM is 20.01%, while EPS Y/Y TTM is -14.20%. This combination usually means revenue is improving faster than profits (margin pressure or cost timing).
EPS trajectory by horizon: EPS next quarter shows 131.41% (field aligns with the EPS Q/Q-type metric), EPS past 3/5Y is shown as -44.15% (negative longer-term earnings growth historically). Net: short-term expected rebound vs weaker historical earnings growth.
Surprise signal: EPS/Sales “Surpr.” is -1.78% (from provided fields). That suggests recent forecasts/prints have not been consistently favorable—important for growth investors who want proof of execution.
Financial Health
Liquidity is acceptable but not “strong fortress”: Quick ratio 1.82 and current ratio 2.30. This indicates good near-term coverage of liabilities.
Leverage: Debt/Eq 2.43 and LT Debt/Eq 2.30 (high). For a cyclical/industrial, this can be manageable, but it increases equity risk during earnings volatility.
Book value and valuation: P/B 1.27 with the above leverage suggests the equity base exists but is not cheaply priced; still, high leverage makes earnings normalization critical.
EV-based metrics are elevated (EV/EBITDA 9.54? actually EV/EBITDA shown as 16.72). This often signals that debt/enterprise adjustments matter materially for valuation vs simple P/E.
Ownership Structure
Insider ownership is 0.42% (low). Insider ownership isn’t a strong positive or negative signal here; it suggests investors are primarily institution-led.
Insider transactions are -0.05% (slightly negative/weak).
Institutional ownership is 81.48% with institutional transactions 0.23% (mildly positive). High institutional ownership can support liquidity and governance, but it also means positioning can be influenced by macro/sector rotations.
Market Performance
Current price is 129.89 with 52W high 169.06 and 52W low 92.45. The stock is ~+40.5% off the low and ~-23% below the high—typical of a volatile/turnaround period.
Performance momentum is negative across many windows: week -1.51%, month -3.49%, quarter -6.20%, YTD -5.58%* (as shown), and 3Y/5Y are notably positive in the dataset’s fields (32.89% and 38.78% shown respectively). Net interpretation: long-run holders may be up, but the current trend is weak.
Analyst “Target Price” shows 130.12 vs current 129.89—essentially flat. That implies limited upside in the near-term consensus unless the earnings rebound is stronger than expected.
Momentum & Volatility
Volatility is moderate-to-high: Volatility 0.23 and ATR (14) 1.51. Beta is 1.03, meaning the stock behaves slightly above market risk.
RSI (14) is 1.78* (this value looks extremely low and may indicate an oversold/mean-reversion reading, but it may also reflect a data formatting/scaling issue). If RSI is indeed extremely low, mean reversion could be near-term; confirm using charting tools before acting.
Short interest: Short float 0.23% and short ratio 0.67. This suggests shorting is not extremely crowded—less risk of a dramatic short squeeze, but also less “contrarian” signal.
Investment Recommendations
value Investor:
With trailing P/E (308.53) distorted by depressed ttm earnings and valuation heavily dependent on normalization, a value entry should be tied to confirmation. Use a “margin-of-safety” approach: consider entries closer to the lower end of the current range (near the 52W low region). A practical value bid zone is $110–$120, which would provide better downside cushion if earnings normalization disappoints.
growth Investor:
Because forward P/E is much lower (16.31) and analysts model a sharp EPS rebound, a growth entry can be closer to current levels—but only if results corroborate guidance. A reasonable growth buy zone is $125–$135 (near current price and consensus target), with tighter risk management if volatility remains elevated.
Investment Summary
DuPont’s ttm P/E (308.5) is inflated by depressed earnings, while forward P/E (16.3), PEG (0.82), and good liquidity support a potential rebound. However, profitability returns are weak/near-zero and margins show net erosion. Growth investors: the model EPS/Sales rebound looks attractive, but it needs execution. Value investors: leverage is high (Debt/Eq ~2.43), so prefer entries with a margin of safety ($110–$120) unless earnings normalize convincingly.
How the News Feels (3 articles)
DuPont (DD) was downgraded by JPMorgan to Neutral from Overweight, with the price target cut to $145 from $172 and the stock removed from the firm's Analyst Focus List. The downgrade attributes a deceleration in short-cycle industrial demand through 2027 as the primary driver. The Fly’s roundup also covers a slate of other upgrades, initiations and downgrades across names, but DD’s note provides a negative read on near-term demand and valuation. Investors may monitor for further weakness signals if demand remains soft and for any signs of a stabilization in the industrial end-market, which would influence DD's price trajectory....
DuPont (DD) announced it will report its third-quarter 2026 results on November 3, 2026, at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. The earnings release, supporting materials, and a replay will be posted on DuPont's Investor Relations site, and a live webcast will be available there as well. Dial-in access for the conference call is 888-440-4172 (U.S. toll-free) or +1-646-960-0673, with Conference ID 5994046. DuPont describes itself as a global innovation leader serving healthcare, water, construction, and industrial markets, with additional information on dupont.com and the investor relations site. The press release provides event details but does not include results or guidance....
DuPont announced the winners of its Tyvek Sustainable Healthcare Packaging Awards at the Medical Packaging Conference in Boston (Sept. 30–Oct. 2, 2026). In its third year, the program honors leaders advancing sustainability across the healthcare packaging lifecycle. The 2026 winners span three categories: Packaging (re)Design — Plastic Ingenuity, which unveiled a ready-to-use tub and lid platform made from recycled PuraForm 134 polyester; paired with Tyvek, the design cuts plastic use by 15% and avoids 217 metric tons of CO2e per 1 million units while remaining recyclable. Operational Efficiencies — Coligroup Spa, which redesigned traditional suture packaging to remove an entire layer of material by using an aluminum inner pouch with a Tyvek strip, enabling sterilizing gas penetration and reducing material, labor and sterilization costs by up to 35%. Sustainability In-Use — Nelipak Healthcare Packaging, with Ecovate headerbags, a mono-material polyethylene laminate combining MOPE with Tyvek and Renewable Attribution; recyclable per Institut Cyclos-HTP and potentially lowering greenhouse gas footprint by up to 40% including end-of-life recycling, aiding packaging circularity in the ready-to-fill/use market. DuPont argues the winners show progress through practical design, operational improvements and material innovations. Lesley Aulick, Tyvek global business director, highlighted Tyvek's role in advancing circularity, reducing environmental impact and protecting patient safety. The awards program supports Tyvek's efforts to push a more circular economy across the healthcare packaging supply chain, with 2027 applications expected to open later....
